{"id":18590,"date":"2026-05-21T23:36:20","date_gmt":"2026-05-21T23:36:20","guid":{"rendered":"https:\/\/www.europesays.com\/france\/18590\/"},"modified":"2026-05-21T23:36:20","modified_gmt":"2026-05-21T23:36:20","slug":"sanofi-sny-announces-financial-results-for-q1-2026","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/france\/18590\/","title":{"rendered":"Sanofi (SNY) Announces Financial Results for Q1 2026"},"content":{"rendered":"\n

Sanofi (NASDAQ:SNY<\/a>) is one of\u00a0the best stem cell therapy stocks to buy<\/a>. Sanofi (NASDAQ:SNY) announced financial results for fiscal Q1 2026 on April 23, reporting double-digit sales and business EPS growth. Fiscal Q1 sales growth was 13.6% at CER, while business earnings per share reached \u20ac1.88. Pharma launches sales rose by 49.6% and reached \u20ac1.2 billion, driven primarily by Ayvakit, ALTUVIIIO, and Sarclisa.<\/p>\n

\"Is Is Sanofi (SNY)the Best Gene-Editing Stock to Buy? <\/p>\n

Management further reported that Dupixent sales grew by 30.8% to \u20ac4.2 billion, suggesting a solid start to 2026. Similarly, vaccine sales grew by 2.1% to \u20ac1.3 billion, benefiting from Heplisav-B. Sanofi (NASDAQ:SNY) also announced that Research and Development expenses reached \u20ac1.7 billion, up by 1.5%, while selling and general expenses reached \u20ac2.3 billion, up by 11.6%, primarily due to the effect of recent acquisitions.<\/p>\n

The company also provided insights into its pipeline progress, with five regulatory approvals, all in immunology, and positive pipeline readouts, including venglustat in the rare disease GD3 (phase 3) and lunsekimig in respiratory diseases (phase 2). Sanofi (NASDAQ:SNY) also reported two regulatory submission acceptances, one phase 3 study start, and four regulatory designations (breakthrough, orphan).<\/p>\n

Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company\u2019s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.<\/p>\n

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/a>.<\/p>\n

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years<\/a> AND 12 Best Stocks That Will Always Grow<\/a>.<\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Sanofi (NASDAQ:SNY) is one of\u00a0the best stem cell therapy stocks to buy. Sanofi (NASDAQ:SNY) announced financial results for…\n","protected":false},"author":2,"featured_media":18591,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[14123,3272,13012,14124],"class_list":["post-18590","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-fiscal-q1-sales-growth","tag-research-and-development","tag-sanofi","tag-stem-cell-therapy"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/18590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=18590"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/18590\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/18591"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=18590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=18590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=18590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}